345 related articles for article (PubMed ID: 22820319)
21. [Use of palivizumab in the prevention of syncytial virus respiratory infection].
Vagnarelli F; Magnani C; Vancini A; Bonacini G; Iori A; Mariani S; Attanasio M; Banchini G
Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():573-5. PubMed ID: 11424809
[TBL] [Abstract][Full Text] [Related]
22. Acute bronchiolitis in infancy as risk factor for wheezing and reduced pulmonary function by seven years in Akershus County, Norway.
Fjaerli HO; Farstad T; Rød G; Ufert GK; Gulbrandsen P; Nakstad B
BMC Pediatr; 2005 Aug; 5():31. PubMed ID: 16109158
[TBL] [Abstract][Full Text] [Related]
23. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T
Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
[TBL] [Abstract][Full Text] [Related]
24. The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children.
Simões EA; Carbonell-Estrany X; Rieger CH; Mitchell I; Fredrick L; Groothuis JR;
J Allergy Clin Immunol; 2010 Aug; 126(2):256-62. PubMed ID: 20624638
[TBL] [Abstract][Full Text] [Related]
25. Severe respiratory syncytial virus bronchiolitis: epidemiologic variations associated with the initiation of palivizumab in severely premature infants with bronchopulmonary dysplasia.
Grimaldi M; Gouyon B; Michaut F; Huet F; Gouyon JB;
Pediatr Infect Dis J; 2004 Dec; 23(12):1081-5. PubMed ID: 15626942
[TBL] [Abstract][Full Text] [Related]
26. Respiratory syncytial virus risk factors in late preterm infants.
Lanari M; Silvestri M; Rossi GA
J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
[TBL] [Abstract][Full Text] [Related]
27. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
28. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
29. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
Lacaze-Masmonteil T; Rozé JC; Fauroux B;
Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
[TBL] [Abstract][Full Text] [Related]
30. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
31. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
32. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
33. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
34. Use of palivizumab in Germany: data from 2002-2007.
Simon A; Nowak H; Sterz R
Klin Padiatr; 2011 Sep; 223(5):292-8. PubMed ID: 21509705
[TBL] [Abstract][Full Text] [Related]
35. Administration of the first dose of palivizumab immunoprophylaxis against respiratory syncytial virus in infants before hospital discharge: what is the evidence for its benefit?
Geskey JM; Ceneviva GD; Brummel GL; Graff GR; Javier MC
Clin Ther; 2004 Dec; 26(12):2130-7. PubMed ID: 15823776
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials.
Simões EAF; Madhi SA; Muller WJ; Atanasova V; Bosheva M; Cabañas F; Baca Cots M; Domachowske JB; Garcia-Garcia ML; Grantina I; Nguyen KA; Zar HJ; Berglind A; Cummings C; Griffin MP; Takas T; Yuan Y; Wählby Hamrén U; Leach A; Villafana T
Lancet Child Adolesc Health; 2023 Mar; 7(3):180-189. PubMed ID: 36634694
[TBL] [Abstract][Full Text] [Related]
37. Long-term airway morbidity following viral LRTI in early infancy: recurrent wheezing or asthma?
Stein RT
Paediatr Respir Rev; 2009 Jun; 10 Suppl 1():29-31. PubMed ID: 19651399
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
39. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
40. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis.
La Via WV; Notario GF; Yu XQ; Sharma S; Noertersheuser PA; Robbie GJ
Pulm Pharmacol Ther; 2013 Dec; 26(6):666-71. PubMed ID: 23523663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
